Skip to content

US · SGMT · BIOTECHNOLOGY

Sagimet Biosciences Inc. (SGMT) intrinsic value and stock valuation

$9.08as of 2026-11-21 · Mkt cap 295.19M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sagimet Biosciences Inc. DCF and intrinsic value

InvestorsCraft values SGMT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SGMT’s statements →

Sagimet Biosciences Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Mateo, CA 94402 sagimet.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-51.04M
20192025
Free cash flow
-$-45.65M
20192025
Total equity
$111.4M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$2M$0.00$0.00
Operating income-$-56.89M-$-54.45M-$-30.74M-$-31.05M-$-23.72M
Net income-$-51.04M-$-45.57M-$-27.88M-$-30.5M-$-24.44M
EPSd-$-1.58M-$-1.45M-$-1.53M-$-1.38M-$-1.1M
Operating cash flow-$-45.65M-$-42.44M-$-23.77M-$-24.49M-$-21.71M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-45.65M-$-42.44M-$-23.77M-$-24.49M-$-21.71M
Total assets$116.5M$160.3M$96.7M$33M$59M
Total debt$80K$80K$70K$210K$350K
Net debt-$-34.94M-$-75.76M-$-75.07M$50K-$-56.38M
Total equity$111.4M$155.8M$91.1M-$-186.95M-$-158.26M
Cash and short-term investments$113.1M$151.3M$94.9M$32.3M$56.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$2M$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$2M$0.00$0.00
Research and development expenses$39.1M$38.4M$19.8M$24.9M$19.3M
Selling, general and administrative expenses$17.8M$16M$13M$6.14M$4.38M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$56.9M$54.5M$32.7M$31.1M$23.7M
Cost and expenses$56.9M$54.5M$32.7M$31.1M$23.7M
Interest income$5.85M$8.89M$2.86M$550K$30K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$130K$0.00
Ebitda-$-51.04M-$-45.57M-$-27.88M-$-30.37M-$-24.44M
Operating income-$-56.89M-$-54.45M-$-30.74M-$-31.05M-$-23.72M
Total other income/expenses, net$5.85M$8.89M$2.86M$560K-$-720K
Income before tax-$-51.04M-$-45.57M-$-27.88M-$-30.5M-$-24.44M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-51.04M-$-45.57M-$-27.88M-$-30.5M-$-24.44M
Weighted average shares outstanding$32.4M$31.4M$18.2M$22.2M$22.2M
Weighted average diluted shares outstanding$32.4M$31.4M$18.2M$22.2M$22.2M
Balance sheet
20252024202320222021
Cash and short-term investments$113.1M$151.3M$94.9M$32.3M$56.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$116.4M$152.8M$96.7M$32.8M$58.7M
Property, plant and equipment, net$80K$80K$70K$210K$340K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$7.41M$0.00$0.00$0.00
Total non-current assets$80K$7.49M$70K$240K$370K
Total assets$116.5M$160.3M$96.7M$33M$59M
Accounts payable$1.31M$1.43M$190K$1.12M$760K
Short-term debt$80K$80K$70K$130K$120K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.1M$4.45M$5.65M$5.28M$2.44M
Long-term debt$0.00$0.00$0.00$80K$220K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$214.7M$214.9M
Capital lease obligations$80K$80K$70K$210K$350K
Total liabilities$5.1M$4.45M$5.65M$220M$217.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-346.35M-$-295.31M-$-249.74M-$-221.87M-$-191.37M
Accumulated other comprehensive income (loss)$120K$230K$30K-$-80K$0.00
Total equity$111.4M$155.8M$91.1M-$-186.95M-$-158.26M
Total investments$78.1M$82.8M$19.8M$32.2M$0.00
Total debt$80K$80K$70K$210K$350K
Net debt-$-34.94M-$-75.76M-$-75.07M$50K-$-56.38M
Cash flow statement
20252024202320222021
Net income-$-51.04M-$-45.57M-$-27.88M-$-30.5M-$-24.44M
Depreciation and amortization$0.00$0.00$0.00$130K$0.00
Stock-based compensation$6.45M$5.29M$4.99M$1.88M$1.9M
Change in working capital-$-1.05M-$-1.05M-$-980K$4.21M-$-60K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$930K-$-910K$120K$0.00$0.00
Net cash provided by operating activities-$-45.65M-$-42.44M-$-23.77M-$-24.49M-$-21.71M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$4.56M-$-61.68M$12.6M-$-32.01M$0.00
Common stock issued$280K$105.8M$89.7M$10K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$280K$104.8M$86.2M-$-70K$9.74M
Net change in cash-$-40.82M$700K$75M-$-56.57M-$-11.97M
Cash at end of period$35M$75.8M$75.1M$160K$56.7M
Operating cash flow-$-45.65M-$-42.44M-$-23.77M-$-24.49M-$-21.71M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-45.65M-$-42.44M-$-23.77M-$-24.49M-$-21.71M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sagimet Biosciences Inc.

        Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

        CEO
        David Happel
        Employees
        16
        Beta
        3.38

        Explore

        Frequently asked questions

        What is the intrinsic value of Sagimet Biosciences Inc. (SGMT)?

        InvestorsCraft does not currently publish an intrinsic value for SGMT. How the IC value is calculated.

        Is SGMT undervalued?

        InvestorsCraft does not publish an undervaluation signal for SGMT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.